In the analysis of the report on Emerging Biopharma companies, prepared and distributed by the IQVIA Institute, today’s attention is focused on therapeutic areas with the most ongoing activity. By far, oncology is the area where most companies are investing their efforts. This is due in pat to strong medical needs, as available therapies are useful but unfortunately frequently fail. It is also due to a better understanding of the pathogenesis of many cancers, which now allows the design of targeted therapies.

Some key highlights of the report include:

  • The leading oncology companies in terms of molecules in development frequently devote over a third of their overall company R&D to oncology.
  • There are 778 emerging biopharma companies with late-stage oncology pipeline activity, with 608 of them 100% focused on oncology.
  • For the 608 companies with a 100% oncology focus, 460 of them have only a single drug in development.
  • Of those developing only a single drug, half of these are investigating this product for more than one indication.
  • The risks inherent in drug development for these companies likely mean that while some will succeed, others whose only compounds fail, will also fail, which has been a relatively common occurrence in the past.

You can read the full text here.

References

  1. Global Trends in R&D. (n.d.). IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred